ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2012 | $360,000 | Replaced |
| 2nd Quarter - Amendment | Oct 29, 2012 | $370,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Issues related to implementation of US-Korea Free Trade Agreement Issues related to Non-tariff trade barriers in Turkey Issues related to US position on intellectual property matters in Canada
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| JACQUELINE POMFRET KIRBY New | — |
| BRADLEY ALLEN ROSSIN | — |
Copyright/Patent/Trademark CPT
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| CARRIE HARNEY | — |
| ANDREW KAPLAN | — |
| JACQUELINE POMFRET KIRBY New | — |
| BRADLEY ALLEN ROSSIN | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Health Issues HCR
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| CARRIE HARNEY | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| JACQUELINE POMFRET KIRBY New | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Medicare/Medicaid MMM
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| CARRIE HARNEY | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| JACQUELINE POMFRET KIRBY New | — |
| BELA SASTRY | — |
Consumer Issues/Safety/Products CSP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD BUCKLEY | — |
| CARRIE HARNEY | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| JACQUELINE POMFRET KIRBY New | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Pharmacy PHA
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE BLOOMQUIST | — |
| RICHARD BUCKLEY | — |
| CARRIE HARNEY | — |
| THERESA JOLIVETTE | — |
| ANDREW KAPLAN | — |
| JACQUELINE POMFRET KIRBY New | — |
| BELA SASTRY | — |
| HEATHER STRAWN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.